Article Correctness Is Author's Responsibility: First-in-human study uses universal donor ‘natural killer cells’ to treat acute myeloid leukemia

(Ohio State University Wexner Medical Center) A new, phase I clinical trial offered The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) will treat patients with relapsed or refractory acute myeloid leukemia (AML) using a novel universal natural killer cell approach. The trial will be conducted in partnership with Kiadis, a clinical stage biopharmaceutical company.